Chronic inflammatory diseases, including debilitating conditions like gout and rheumatoid arthritis, represent significant global health challenges that demand safer, more effective therapeutic ingredients. Traditional non-steroidal anti-inflammatory drugs (NSAIDs) often carry undesirable side effects, driving a compelling market need for natural, high-purity, and highly bioavailable alternatives. CD BioGlyco, leveraging over decades of glycomics expertise, focuses on the enzymatic synthesis of customized, low-molecular-weight seaweed oligosaccharides derived from marine biopolymers. These highly tailored ingredients offer superior systemic bioavailability and targeted action compared to their parent polysaccharides. Our service is designed to provide clients in the pharmaceutical, nutraceutical, and functional food sectors with the highest quality, application-specific seaweed oligosaccharides.
Key Technologies
- Controlled Bioconversion via Lyase and Agarase Engineering
We utilize proprietary, highly specific marine-derived enzymes (lyases and hydrolases, such as various β-agarases) to cleave the parent polysaccharides (e.g., alginate, agar, carrageenan) at precise glycosidic linkages, ensuring the resulting oligosaccharide ingredients possess the exact structural characteristics required for optimal anti-inflammatory and anti-gout activity. This enzyme-driven specificity is key to generating powerful ingredients like customized neoagarooligosaccharides (NAOs).
- Advanced Purification and Fractionation
Following bioconversion, crude hydrolysates are subjected to rigorous purification workflows. We employ techniques such as ultrafiltration (UF), high-performance size exclusion chromatography (HPSEC), and ion-exchange chromatography (IEC) to isolate and concentrate the desired oligosaccharide fractions. This step ensures exceptional purity and structural homogeneity, validating the ingredient's clinical efficacy and minimizing formulation risks.
Seaweed Oligosaccharide: Precision Glyco-Engineered Solutions for Inflammatory Relief
CD BioGlyco offers a comprehensive service scope focused on the design and production of effective natural anti-inflammatory agents, seaweed oligosaccharides. The bioactivity stems from seaweed oligosaccharides from their ability to interact directly with immune signaling pathways. For instance, specific seaweed oligosaccharide types suppress the activation of the NLRP3 inflammasome, a key driver of acute gouty flares, thereby reducing the production of the pro-inflammatory cytokine IL-1β. Furthermore, these compounds effectively inhibit the NF-κB and MAPK signaling cascades, leading to the downregulation of major inflammatory mediators like TNF-α, IL-6, and PGE2.
We have demonstrated that specific seaweed oligosaccharides, such as NAOs derived from agar, possess potent, concentration-dependent anti-inflammatory effects through these precise mechanisms. By controlling the degree of polymerization (DP) and chemical modification of NAOs and other seaweed oligosaccharide types (e.g., carrageenan oligosaccharides, alginate oligosaccharides), we customize their targeting capabilities.
Through our technical methods—specifically, controlled enzymatic depolymerization followed by high-purity fractionation—we provide customers with seaweed oligosaccharide raw materials that meet their specific application needs, whether for oral supplements, topical gels, or drug delivery excipients.
- Custom Synthesis: Production of NAOs, fucoidan oligosaccharides, and alginate oligosaccharides at specific molecular weight ranges (e.g., DP2-10).
- Structural Modification: Chemical modification (e.g., sulfation) to enhance biological activity and bioavailability.
- GMP-Grade Production: Manufacturing processes scaled for preclinical research through commercial production.
Workflow
1. Raw Material Pretreatment
We begin with the selection of high-quality, verified seaweed biomass that is rich in target polysaccharides. Raw materials undergo rigorous quality control (QC) checks, washing, and preliminary conditioning to remove impurities and prepare the matrix for efficient extraction.
2. Polysaccharide Extraction
Proprietary methods, including optimized hydrothermal and mild alkaline extraction, are used to isolate the target high-molecular-weight polysaccharides. The extraction parameters are finely tuned to preserve the chemical integrity and structure of the polymer.
3. Enzymatic Bioconversion
The purified polysaccharide is subjected to controlled hydrolysis using specialized enzymes (e.g., β-agarase for NAOs). Reaction conditions (temperature, pH, reaction time) are rigorously monitored and adjusted to control the depolymerization process, achieving the target average molecular weight and DP.
4. Purification and Fractionation
The oligosaccharide solution is purified to remove residual enzymes, salts, and low-activity components. High-resolution chromatographic techniques are deployed to isolate narrow-range fractions, ensuring the final ingredient meets stringent purity and molecular weight specifications.
5. Structural Characterization
Every batch undergoes exhaustive structural analysis using nuclear magnetic resonance (NMR) and mass spectrometry (MS) to confirm the chemical structure, glycosidic linkages, and degree of sulfation. Biological validation is performed via in vitro assays to confirm targeted anti-inflammatory activity.
6. Custom Formulation and Delivery
The final, validated oligosaccharide material is processed into the client's preferred format (e.g., lyophilized powder, solution). Comprehensive documentation, including QC reports and structural data, is provided to facilitate regulatory filing and application development.
Publication Data
DoI: doi.org/10.3390/md20080500
Journal: Marine Drugs
IF: 5.4
Published: 2022
Results: This article presents two randomized, double-blind, placebo-controlled clinical studies investigating the effects of SXRG84, a sulfated polysaccharide derived from the green seaweed Ulva sp. 84, on overweight and obese participants. Study 1 tested doses of 2 g/day and 4 g/day of SXRG84, finding that the 2 g/day dose significantly reduced non-HDL cholesterol (-10%) and the atherogenic index (-50%) in overweight participants, while the 4 g/day dose lowered CRP (-27%, a key inflammatory marker). Study 2 used a 2 g/day dose and did not replicate the lipid-lowering effects but confirmed SXRG84's anti-inflammatory activity, with significant reductions in proinflammatory cytokines (IFN-γ, IL-1β, TNF-α) and the anti-inflammatory cytokine IL-10 at 12 weeks. Overall, SXRG84 showed consistent anti-inflammatory effects and participant-specific benefits on plasma lipids, with no adverse health impacts, highlighting its potential as a preventive or adjunctive therapy for metabolic-related inflammation.
Fig.1 The mean change in non-HDL cholesterol and the atherogenic index of plasma after treatment with placebo and active treatments. (Roach, et al., 2022)
Applications
- Immune System Activation
They activate key immune cells, including macrophages, T-lymphocytes, and natural killer cells, prompting them to increase the production of anti-tumor cytokines like IL-2 and TNF-α.
- Inhibition of Metastasis
Studies suggest that certain seaweed oligosaccharides interfere with signaling pathways that regulate cancer cell proliferation, invasion, and metastasis, offering potential as an adjuvant therapy.
- Gut Health and Mucosal Immunity
Oligosaccharides act as prebiotics, beneficially modulating the gut microbiota, which is intrinsically linked to systemic immune regulation. They suppress intestinal inflammation (e.g., in colitis models).
- Vaccine Adjuvants
Due to their ability to activate innate immune cells and promote antigen presentation, seaweed oligosaccharides are explored as safe, natural adjuvants to enhance the efficacy of both prophylactic and therapeutic vaccines.
Advantages
- Unrivaled Glyco-Specific Purity
We guarantee purity levels exceeding 98%, achieved through our multi-stage chromatographic isolation. This eliminates inactive impurities, ensuring high efficacy and compliance.
- Molecular Weight Precision
Our proprietary enzymatic methods allow for tight control over the final oligosaccharide DP and MW, a critical factor known to influence bioactivity and absorption.
- Mechanism-Focused Validation
Beyond standard quality metrics, every ingredient batch is validated using advanced immunological assays to confirm the desired anti-inflammatory potency.
- Exceptional Experience
We have successfully provided numerous clients with seaweed oligosaccharide raw materials that meet their research needs for the development of highly effective anti-inflammatory drugs.
Frequently Asked Questions
Can I request a specific DP for my oligosaccharide batch?
Absolutely. Our enzymatic method is designed for precision. We welcome requests for specific DP ranges (e.g., DP4-6) or specific average molecular weights. Please detail your specifications in your initial inquiry.
What is the risk of contamination from heavy metals or marine toxins?
We maintain a rigorous quality control process. Our seaweed sources are traceable, and the final purification steps include stringent checks for heavy metals and marine biotoxins, ensuring the final ingredient meets international safety standards.
Are seaweed oligosaccharides stable during processing and storage?
Yes. Low-molecular-weight oligosaccharides are generally highly stable. We recommend storage as a lyophilized powder or in a stable solution, and we provide application-specific stability data to guide your formulation.
Customer Review
"The high-purity neoagarooligosaccharides provided by CD BioGlyco were instrumental in our successful launch of a joint health supplement. Their ability to deliver a tightly controlled DP fraction, confirmed by their rigorous NMR and HPSEC data, gave us the confidence needed to make strong, evidence-based claims. The batch-to-batch consistency has been flawless, allowing us to scale production efficiently without any quality drift."
- Dr. E.M., Leading Nutraceutical Developer
"We chose CD BioGlyco for their mechanism-focused validation. Their custom seaweed oligosaccharides showed remarkable NLRP3 inflammasome inhibition in our in vitro models, far exceeding the activity of commercially available, high-MW extracts. This level of purity and targeted activity has significantly accelerated our preclinical candidate selection process."
- E.C., Preclinical Drug Discovery Lab
"We sought a high-end, natural ingredient for an anti-redness cream. The low-molecular-weight alginate oligosaccharide fraction developed by their team was stable in our complex matrix and demonstrated excellent skin-calming anti-inflammatory activity in consumer trials. Their technical support throughout the formulation phase was highly valuable."
– A.O., Topical Cosmetic Company
Associated Services
CD BioGlyco's anti-gout and anti-inflammatory seaweed oligosaccharide ingredient production service combines proprietary enzymatic technology with rigorous structural validation to deliver functional ingredients of unparalleled quality. Please feel free to contact us for detailed consultations, technical data, and tailored project proposals.
Reference
- Roach, L.A.; et al. Improved plasma lipids, anti-inflammatory activity, and microbiome shifts in overweight participants: two clinical studies on oral supplementation with algal sulfated polysaccharide. Marine Drugs. 2022, 20(8): 500. (Open Access)
